The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of daratumumab in combination for untreated multiple myeloma when stem cell transplant is suitable.
Following on from information received from the company this appraisal has now been scheduled into the work programme.
The appraisal is anticipated to begin during late June 2020 when we will write to you about how you can get involved.